ESMO: Facing new Keytruda combos from Merck, BMS touts 5-year kidney cancer data for Opdivo-Yervoy

Bristol Myers Squibb’s combination of Opdivo and Yervoy was the first immuno-oncology regimen to snag an FDA approval for newly diagnosed kidney cancer. While multiple therapies have since entered the market, the New York pharma is now trumpeting five-year data to fend off competition.